Economic Impact of Venous Thromboembolism After Hip and Knee Arthroplasty

Potential Impact of Rivaroxaban

Richard J Friedman; Nishan Sengupta; Michael Lees


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(3):299-306. 

In This Article

Five-year View

Rivaroxaban is one of a number of new oral anticoagulants in development; the other most advanced ones are the direct factor Xa inhibitor apixaban and the direct thrombin inhibitor dabigatran.[72,75] They all overcome the drawbacks associated with the established anticoagulants and have characteristics that simplify their use. These include an oral route of administration, no requirement for routine coagulation monitoring, a wide therapeutic window, rapid onset and offset of action, and minimal interactions with food or other drugs.[77,78] Adoption of these agents over the next 5 years, not only for thromboprophylaxis after THA or TKA, but also for use in other patients at risk for VTE, such as acutely ill medical patients, patients with atrial fibrillation or acute coronary syndromes and those with the likelihood of recurrent VTE, will dramatically change treatment paradigms. The new agents should reduce the burden on the healthcare system and improve patient adherence to therapy, with the result of a substantial improvement in the health of these patient groups.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.